Table 1 Clinical-pathological parameters of patients with prostate cancer and non-malignant prostate disease
From: Alterations of global histone H4K20 methylation during prostate carcinogenesis
PCA (n = 113) | BPH (n = 17) | normal (n = 6) | |
|---|---|---|---|
serum PSA | |||
< 4 ng/ml | 9 (7.9%) | 0 (0.0%) | 0 (0.0%) |
4-10 ng/ml | 48 (42.5%) | 2 (11.7%) | 0 (0.0%) |
> 10 ng/ml | 48 (42.5%) | 2 (11.7%) | 0 (0.0%) |
n.a. | 8 (7.1%) | 13 (76.5%) | 6 (100%) |
digital rectal examination | |||
normal | 51 (45.1%) | ||
suspicious | 50 (44.2%) | ||
n.a. | 12 (10.6%) | ||
pathological stage | |||
pT2 | 61 (54.0%) | ||
pT3a | 33 (29.2%) | ||
pT3b | 16 (14.1%) | ||
pT4 | 3 (2.6%) | ||
seminal vesicle infiltration | 18 (15.8%) | ||
lymph node metastasis | 9 (7.9%) | ||
Gleason Score | |||
< 7 | 48 (42.5%) | ||
3 + 4 = 7 | 11 (9.8%) | ||
4 + 3 = 7 | 11 (9.8%) | ||
8-10 | 43 (38.0%) |